vs
CareDx, Inc.（CDNA）与LiveRamp Holdings, Inc.（RAMP）财务数据对比。点击上方公司名可切换其他公司
LiveRamp Holdings, Inc.的季度营收约是CareDx, Inc.的1.8倍（$212.2M vs $117.7M），LiveRamp Holdings, Inc.净利率更高（18.8% vs 2.4%，领先16.4%），CareDx, Inc.同比增速更快（39.0% vs 8.6%），过去两年CareDx, Inc.的营收复合增速更高（12.9% vs 11.1%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
LiveRamp Holdings, Inc.是一家美国SaaS企业，核心业务为提供数据连接平台，服务涵盖数据导入、线下数据线上迁移等能力，助力企业开展营销相关的数据应用，为品牌及营销从业者的数字化运营提供技术支撑。
CDNA vs RAMP — 直观对比
营收规模更大
RAMP
是对方的1.8倍
$117.7M
营收增速更快
CDNA
高出30.4%
8.6%
净利率更高
RAMP
高出16.4%
2.4%
两年增速更快
CDNA
近两年复合增速
11.1%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $117.7M | $212.2M |
| 净利润 | $2.8M | $39.9M |
| 毛利率 | — | 71.9% |
| 营业利润率 | 1.0% | 18.6% |
| 净利率 | 2.4% | 18.8% |
| 营收同比 | 39.0% | 8.6% |
| 净利润同比 | — | 255.7% |
| 每股收益（稀释后） | $0.05 | $0.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNARAMP
| Q1 26 | $117.7M | — | ||
| Q4 25 | $108.4M | $212.2M | ||
| Q3 25 | $100.1M | $199.8M | ||
| Q2 25 | $86.7M | $194.8M | ||
| Q1 25 | $84.7M | $188.7M | ||
| Q4 24 | $86.6M | $195.4M | ||
| Q3 24 | $82.9M | $185.5M | ||
| Q2 24 | $92.3M | $176.0M |
净利润CDNARAMP
| Q1 26 | $2.8M | — | ||
| Q4 25 | $-4.1M | $39.9M | ||
| Q3 25 | $1.7M | $27.4M | ||
| Q2 25 | $-8.6M | $7.7M | ||
| Q1 25 | $-10.4M | $-6.3M | ||
| Q4 24 | $87.7M | $11.2M | ||
| Q3 24 | $-10.6M | $1.7M | ||
| Q2 24 | $-4.6M | $-7.5M |
毛利率CDNARAMP
| Q1 26 | — | — | ||
| Q4 25 | — | 71.9% | ||
| Q3 25 | — | 70.2% | ||
| Q2 25 | — | 70.1% | ||
| Q1 25 | — | 69.3% | ||
| Q4 24 | — | 71.9% | ||
| Q3 24 | — | 72.4% | ||
| Q2 24 | — | 70.6% |
营业利润率CDNARAMP
| Q1 26 | 1.0% | — | ||
| Q4 25 | -5.6% | 18.6% | ||
| Q3 25 | -0.2% | 10.7% | ||
| Q2 25 | -12.8% | 3.7% | ||
| Q1 25 | -15.8% | -6.1% | ||
| Q4 24 | 97.5% | 7.5% | ||
| Q3 24 | -16.6% | 4.0% | ||
| Q2 24 | -7.9% | -3.0% |
净利率CDNARAMP
| Q1 26 | 2.4% | — | ||
| Q4 25 | -3.8% | 18.8% | ||
| Q3 25 | 1.7% | 13.7% | ||
| Q2 25 | -9.9% | 4.0% | ||
| Q1 25 | -12.2% | -3.3% | ||
| Q4 24 | 101.3% | 5.7% | ||
| Q3 24 | -12.8% | 0.9% | ||
| Q2 24 | -5.0% | -4.3% |
每股收益（稀释后）CDNARAMP
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-0.08 | $0.62 | ||
| Q3 25 | $0.03 | $0.42 | ||
| Q2 25 | $-0.16 | $0.12 | ||
| Q1 25 | $-0.19 | $-0.10 | ||
| Q4 24 | $1.60 | $0.17 | ||
| Q3 24 | $-0.20 | $0.03 | ||
| Q2 24 | $-0.09 | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $403.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $962.3M |
| 总资产 | $411.1M | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDNARAMP
| Q1 26 | $77.9M | — | ||
| Q4 25 | $177.2M | $403.4M | ||
| Q3 25 | $194.2M | $376.9M | ||
| Q2 25 | $186.3M | $371.1M | ||
| Q1 25 | $230.9M | $420.8M | ||
| Q4 24 | $260.7M | $384.3M | ||
| Q3 24 | $240.9M | $348.4M | ||
| Q2 24 | $228.9M | $342.7M |
总债务CDNARAMP
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — |
股东权益CDNARAMP
| Q1 26 | — | — | ||
| Q4 25 | $303.1M | $962.3M | ||
| Q3 25 | $311.1M | $943.8M | ||
| Q2 25 | $327.4M | $947.8M | ||
| Q1 25 | $379.3M | $948.9M | ||
| Q4 24 | $378.4M | $957.7M | ||
| Q3 24 | $273.2M | $932.1M | ||
| Q2 24 | $264.7M | $951.9M |
总资产CDNARAMP
| Q1 26 | $411.1M | — | ||
| Q4 25 | $413.2M | $1.3B | ||
| Q3 25 | $432.3M | $1.2B | ||
| Q2 25 | $444.3M | $1.2B | ||
| Q1 25 | $489.6M | $1.3B | ||
| Q4 24 | $491.1M | $1.3B | ||
| Q3 24 | $477.0M | $1.2B | ||
| Q2 24 | $466.8M | $1.2B |
负债/权益比CDNARAMP
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | — |
| 自由现金流经营现金流 - 资本支出 | $514.0K | — |
| 自由现金流率自由现金流/营收 | 0.4% | — |
| 资本支出强度资本支出/营收 | — | 0.1% |
| 现金转化率经营现金流/净利润 | 1.54× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CDNARAMP
| Q1 26 | $4.3M | — | ||
| Q4 25 | $21.4M | — | ||
| Q3 25 | $37.4M | $57.4M | ||
| Q2 25 | $9.9M | $-15.8M | ||
| Q1 25 | $-26.6M | — | ||
| Q4 24 | $21.9M | $45.1M | ||
| Q3 24 | $12.5M | $55.6M | ||
| Q2 24 | $18.9M | $-9.3M |
自由现金流CDNARAMP
| Q1 26 | $514.0K | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $56.8M | ||
| Q2 25 | — | $-16.2M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $44.8M | ||
| Q3 24 | — | $55.4M | ||
| Q2 24 | — | $-9.6M |
自由现金流率CDNARAMP
| Q1 26 | 0.4% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 28.4% | ||
| Q2 25 | — | -8.3% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 22.9% | ||
| Q3 24 | — | 29.8% | ||
| Q2 24 | — | -5.4% |
资本支出强度CDNARAMP
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.1% |
现金转化率CDNARAMP
| Q1 26 | 1.54× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 22.30× | 2.09× | ||
| Q2 25 | — | -2.04× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | 4.02× | ||
| Q3 24 | — | 32.10× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Financial Results Total | $85.0M | 72% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
| Other | $6.4M | 5% |
RAMP
暂无分部数据
